What's new

Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 24, Status: Authorised

Feb 20, 2025 - 15:02
 0
Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 24, Status: Authorised
Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 24, Status: Authorised
Read More

Tags:

Previous Article

Orphan designation: volixibat potassium Treatment of primary biliary cholangitis...

Next Article

Orphan designation: Allogenic umbilical cord-derived osteoblast cells Treatment ...

Related Posts

Human medicines European public assessment report (EPAR): Alimta, pemetrexed, Date of authorisation: 20/09/2004, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 5, 2025  0

Human medicines European public assessment report (EPAR): Xenpozyme, olipudase alfa, Date of authorisation: 24/06/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 26, 2025  0

Summary of opinion: Kaftrio, 27/02/2025 Positive

Summary of opinion: Kaftrio, 27/02/2025 Positive

Feb 28, 2025  0